Tuberculosis in children: Difference between revisions
Mohamed riad (talk | contribs) |
|||
(12 intermediate revisions by 4 users not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{CMG}}; {{AE}} {{AL}} | |||
{{CMG}}; {{AE}} {{Mashal Awais}}; {{AL}} | |||
{{Tuberculosis}} | {{Tuberculosis}} | ||
==Overview== | ==Overview== | ||
Tuberculosis in children aged 15 years or younger is a public health | [[Tuberculosis]] in children aged 15 years or younger is considered a [[public health]] issue of special significance because it is a [[marker]] for recent [[Transmission (medicine)|transmission]] of TB. The likelihood of developing life-threatening forms of tuberculosis, such as [[miliary TB]] or [[TB meningitis]] is more in [[Infant|infants]] and young [[children]]. [[Screening]] in children is essential, because the [[signs]] and [[Symptom|symptoms]] are usually vague or non-specific. History of close contact with [[tuberculosis]] patients plays an major role in the [[diagnosis]] of TB in children. The [[treatment]] is similar to adults, with adjustment of the doses according to the child's weight. | ||
==Screening for Tuberculosis== | ==Screening for Tuberculosis== | ||
===Symptom-based Screening Approach === | ===Symptom-based Screening Approach=== | ||
<small><small>Algorithm adapted from Guidance for National Tuberculosis Programmes on the Management of Tuberculosis in Children<ref name="WHO TB Children"> {{cite web |url=http://apps.who.int/iris/bitstream/10665/112360/1/9789241548748_eng.pdf| title=WHO Guidance for national tuberculosis programmes on the management of tuberculosis in children, 2014}} </ref></small></small> | <small><small>Algorithm adapted from Guidance for National Tuberculosis Programmes on the Management of Tuberculosis in Children<ref name="WHO TB Children"> {{cite web |url=http://apps.who.int/iris/bitstream/10665/112360/1/9789241548748_eng.pdf| title=WHO Guidance for national tuberculosis programmes on the management of tuberculosis in children, 2014}} </ref></small></small> | ||
<div style=" font-size: 95%;"> | <div style=" font-size: 95%;">{{Family tree/start}} | ||
{{Family tree/start}} | |||
{{family tree |boxstyle = border-radius: 5px 5px 5px 5px;| | | | | | | | | | A01 | | | | | | | | |A01=<div style="float: left; text-align: center; line-height: 150%; width: 13em">Child in close contact with a confirmed TB case</div>}} | {{family tree |boxstyle = border-radius: 5px 5px 5px 5px;| | | | | | | | | | A01 | | | | | | | | |A01=<div style="float: left; text-align: center; line-height: 150%; width: 13em">Child in close contact with a confirmed TB case</div>}} | ||
{{family tree | | | | |,|-|-|-|-|-|^|-|-|-|-|-|.| | | | | | | }} | {{family tree | | | | |,|-|-|-|-|-|^|-|-|-|-|-|.| | | | | | | }} | ||
Line 54: | Line 54: | ||
==Diagnosis== | ==Diagnosis== | ||
*Children must have a complete evaluation for tuberculosis, which includes a meticulous medical history, a complete physical examination, [[tuberculin skin test]] ([[TST]]), [[chest X-ray]], [[sputum]] or gastric aspirate studies ([[microscopy]] and culture), and [[HIV]] testing. | *Children must have a complete evaluation for tuberculosis, which includes a meticulous medical history, a complete physical examination, [[tuberculin skin test]] ([[TST]]), [[chest X-ray]], [[sputum]] or gastric aspirate studies ([[microscopy]] and culture), and [[HIV]] testing. | ||
*Bacteriological testing might be difficult among children, but it should be performed whenever possible. | *Bacteriological testing might be difficult among children, but it should be performed whenever possible. | ||
*Adolescents usually have the adult clinical presentation, but may also present with symptoms and findings seen in smaller children. | *Adolescents usually have the adult clinical presentation, but may also present with symptoms and findings seen in smaller children. | ||
*Even though a scoring system has been developed in some countries<ref>{{Cite journal | *Even though a scoring system has been developed in some countries<ref>{{Cite journal | ||
| author = [[Isabella Coimbra]], [[Magda Maruza]], [[Maria de Fatima Pessoa Militao Albuquerque]], [[Joanna D.'Arc Lyra Batista]], [[Maria Cynthia Braga]], [[Libia Vilela Moura]], [[Democrito Barros Miranda-Filho]], [[Ulisses Ramos Montarroyos]], [[Heloisa Ramos Lacerda]], [[Laura Cunha Rodrigues]] & [[Ricardo Arraes de Alencar Ximenes]] | | author = [[Isabella Coimbra]], [[Magda Maruza]], [[Maria de Fatima Pessoa Militao Albuquerque]], [[Joanna D.'Arc Lyra Batista]], [[Maria Cynthia Braga]], [[Libia Vilela Moura]], [[Democrito Barros Miranda-Filho]], [[Ulisses Ramos Montarroyos]], [[Heloisa Ramos Lacerda]], [[Laura Cunha Rodrigues]] & [[Ricardo Arraes de Alencar Ximenes]] | ||
Line 110: | Line 111: | ||
| doi = 10.1155/2012/401896 | | doi = 10.1155/2012/401896 | ||
| pmid = 22848799 | | pmid = 22848799 | ||
}}</ref>, the WHO does not recommend this system for the evaluation of children with suspected TB.<ref name="WHO TB Children"> {{cite web |url=http://apps.who.int/iris/bitstream/10665/112360/1/9789241548748_eng.pdf| title=WHO Guidance for national tuberculosis programmes on the management of tuberculosis in children, 2014}}</ref> | }}</ref>, the WHO does not recommend this system for the evaluation of children with suspected TB.<ref name="WHO TB Children"> {{cite web |url=http://apps.who.int/iris/bitstream/10665/112360/1/9789241548748_eng.pdf| title=WHO Guidance for national tuberculosis programmes on the management of tuberculosis in children, 2014}}</ref> | ||
{| style="border: 0px; font-size: 90%; margin: 3px; width: 700px;" align=center | {| style="border: 0px; font-size: 90%; margin: 3px; width: 700px;" align="center" | ||
|valign=top| | | valign="top" | | ||
|+ | |+ | ||
! style="background: #4479BA;" | ! colspan="2" style="background: #4479BA;" |{{fontcolor|#FFF|Diagnostic Approach in Children with Suspected Tuberculosis}} | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; width: 200px;" | History and Symptoms | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; width: 200px;" |History and Symptoms | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Evaluate for close contact with a case of TB. <br> | *Evaluate for close contact with a case of TB. <br> | ||
*Symptoms include [[cough]], [[fever]], [[poor appetite]], [[weight loss]], [[lethargy]], [[fatigue]]. | *Symptoms include [[cough]], [[fever]], [[poor appetite]], [[weight loss]], [[lethargy]], [[fatigue]]. | ||
*Growth chart should be evaluated to determine an altered growth development. | *Growth chart should be evaluated to determine an altered growth development. | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | Physical Examination | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Physical Examination | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*The physical examination might be unremarkable in children. <br> | *The physical examination might be unremarkable in children. <br> | ||
*Extrapulmonary tuberculosis presents with abnormal physical findings. | *Extrapulmonary tuberculosis presents with abnormal physical findings. | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | Tuberculin Skin Test | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Tuberculin Skin Test | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Important for | *Important for evaluating children with no history of close contact and to screen for TB infection. <br> | ||
*In immunocompetent children, > 10 mm is considered positive. <br> | *In immunocompetent children, > 10 mm is considered positive. <br> | ||
*In | *In immunosuppressed children, > 5mm is considered positive. | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | Chest X-ray | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Chest X-ray | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Common findings include consolidation associated with an enlarged [[lymph node]] in the | *Common findings include consolidation associated with an enlarged [[lymph node]] in the hilum. <br> | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | Bacteriological Tests | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Bacteriological Tests | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Sputum or gastric aspirates should be assessed for the presence of [[M. tuberculosis]].<br> | *Sputum or gastric aspirates should be assessed for the presence of [[M. tuberculosis]].<br> | ||
*Microscopy and culture should be done in every case possible to confirm the diagnosis. | *Microscopy and culture should be done in every case possible to confirm the diagnosis. | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | HIV Test | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |HIV Test | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*In children with suspected TB, [[HIV]] testing should be offered. | *In children with suspected TB, [[HIV]] testing should be offered. | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | colspan="2" style="padding: 5px 5px; background: #F5F5F5;" |<small> Adapted from Guidance for National Tuberculosis Programmes on the Management of Tuberculosis in Children<ref name="WHO TB Children"> {{cite web |url=http://apps.who.int/iris/bitstream/10665/112360/1/9789241548748_eng.pdf| title=WHO Guidance for national tuberculosis programmes on the management of tuberculosis in children, 2014}}</ref></small> | ||
|- | |- | ||
|} | |} | ||
===Diagnostic Approach for Extrapulmonary Tuberculosis=== | ===Diagnostic Approach for Extrapulmonary Tuberculosis=== | ||
{| style="border: 0px; font-size: 90%; margin: 3px; width: 700px;" align=center | {| style="border: 0px; font-size: 90%; margin: 3px; width: 700px;" align="center" | ||
|valign=top| | | valign="top" | | ||
|+ | |+ | ||
! style="background: #4479BA;"| {{fontcolor|#FFF|Location}} | ! style="background: #4479BA;" |{{fontcolor|#FFF|Location}} | ||
! style="background: #4479BA;"| {{fontcolor|#FFF|Common Clinical Presentation}} | ! style="background: #4479BA;" |{{fontcolor|#FFF|Common Clinical Presentation}} | ||
! style="background: #4479BA;"| {{fontcolor|#FFF|Diagnostic Workup}} | ! style="background: #4479BA;" |{{fontcolor|#FFF|Diagnostic Workup}} | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; width: 175px;" | Peripheral [[Adenopathy]] | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; width: 175px;" |Peripheral [[Adenopathy]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Painless [[lymph node]] enlargement, commonly in one side of the neck. | | style="padding: 5px 5px; background: #F5F5F5;" |Painless [[lymph node]] enlargement, commonly in one side of the neck. | ||
| style="padding: 5px 5px; background: #F5F5F5;" |[[Fine needle aspiration]] or [[biopsy]] of the [[lymph node]], culture of aspirate. | | style="padding: 5px 5px; background: #F5F5F5;" |[[Fine needle aspiration]] or [[biopsy]] of the [[lymph node]], culture of aspirate. | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | [[Miliary Tuberculosis]] | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |[[Miliary Tuberculosis]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" |[[Lethargy]], [[fever]], non-specific symptoms. | | style="padding: 5px 5px; background: #F5F5F5;" |[[Lethargy]], [[fever]], non-specific symptoms. | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Order a [[chest X-ray]] and a [[lumbar puncture]] in suspicion of [[meningeal]] involvement. | | style="padding: 5px 5px; background: #F5F5F5;" |Order a [[chest X-ray]] and a [[lumbar puncture]] in suspicion of [[meningeal]] involvement. | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | Tuberculous Meningitis | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Tuberculous Meningitis | ||
| style="padding: 5px 5px; background: #F5F5F5;" |[[Lethargy]], [[neck stiffness]], [[headache]], [[irritability]], bulging [[fontanelle]]. | | style="padding: 5px 5px; background: #F5F5F5;" |[[Lethargy]], [[neck stiffness]], [[headache]], [[irritability]], bulging [[fontanelle]]. | ||
| style="padding: 5px 5px; background: #F5F5F5;" |[[Lumbar puncture]], head CT. | | style="padding: 5px 5px; background: #F5F5F5;" |[[Lumbar puncture]], head CT. | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | Pleural Effusion | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Pleural Effusion | ||
| style="padding: 5px 5px; background: #F5F5F5;" | Decreased breath sounds, dullness to percussion, chest pain. | | style="padding: 5px 5px; background: #F5F5F5;" |Decreased breath sounds, dullness to percussion, chest pain. | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Order a [[chest X-ray]], perform an analysis of the [[pleural fluid]]. | | style="padding: 5px 5px; background: #F5F5F5;" |Order a [[chest X-ray]], perform an analysis of the [[pleural fluid]]. | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | Tuberculous Peritonitis | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Tuberculous Peritonitis | ||
| style="padding: 5px 5px; background: #F5F5F5;" | Order an abdominal [[ultrasound]], consider [[ascites|abdominal fluid]] aspiration for analysis. | | style="padding: 5px 5px; background: #F5F5F5;" |Order an abdominal [[ultrasound]], consider [[ascites|abdominal fluid]] aspiration for analysis. | ||
| style="padding: 5px 5px; background: #F5F5F5;" | [[Abdominal tenderness]], [[ascites]]. | | style="padding: 5px 5px; background: #F5F5F5;" |[[Abdominal tenderness]], [[ascites]]. | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | Bone or Joint Infection | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Bone or Joint Infection | ||
| style="padding: 5px 5px; background: #F5F5F5;" | Altered [[range of motion|ROM]], [[joint swelling]], mono[[arthralgia|articular pain]]. | | style="padding: 5px 5px; background: #F5F5F5;" |Altered [[range of motion|ROM]], [[joint swelling]], mono[[arthralgia|articular pain]]. | ||
| style="padding: 5px 5px; background: #F5F5F5;" | [[X-ray]] of the affected limb, [[joint]] fluid aspiration and analysis. | | style="padding: 5px 5px; background: #F5F5F5;" |[[X-ray]] of the affected limb, [[joint]] fluid aspiration and analysis. | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | [[Tuberculous Pericarditis]] | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |[[Tuberculous Pericarditis]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Distant [[heart sounds]], [[tachycardia]], signs of [[heart failure]] ([[edema]], [[dyspnea]]). | | style="padding: 5px 5px; background: #F5F5F5;" |Distant [[heart sounds]], [[tachycardia]], signs of [[heart failure]] ([[edema]], [[dyspnea]]). | ||
| style="padding: 5px 5px; background: #F5F5F5;" |[[Echocardiography]], consider [[pericardiocentesis]] for fluid analysis. | | style="padding: 5px 5px; background: #F5F5F5;" |[[Echocardiography]], consider [[pericardiocentesis]] for fluid analysis. | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | colspan="3" style="padding: 5px 5px; background: #F5F5F5;" |<small> Adapted from Guidance for National Tuberculosis Programmes on the Management of Tuberculosis in Children<ref name="WHO TB Children"> {{cite web |url=http://apps.who.int/iris/bitstream/10665/112360/1/9789241548748_eng.pdf| title=WHO Guidance for national tuberculosis programmes on the management of tuberculosis in children, 2014}}</ref> and WHO Childhood TB: Training Toolkit <ref name="Toolkit"> {{cite web| url=http://www.who.int/tb/challenges/childtbtraining_manual/en/| title=WHO Childhood TB: Training Toolkit}}</ref> | ||
</small> | </small> | ||
|- | |- | ||
Line 193: | Line 194: | ||
==Treatment <small><small><small> Adapted from Guidance for National Tuberculosis Programmes on the Management of Tuberculosis in Children<ref name="WHO TB Children"> {{cite web |url=http://apps.who.int/iris/bitstream/10665/112360/1/9789241548748_eng.pdf| title=WHO Guidance for national tuberculosis programmes on the management of tuberculosis in children, 2014}}</ref> and WHO Childhood TB: Training Toolkit <ref name="Toolkit"> {{cite web| url=http://www.who.int/tb/challenges/childtbtraining_manual/en/| title=WHO Childhood TB: Training Toolkit}}</ref></small></small></small>== | ==Treatment <small><small><small> Adapted from Guidance for National Tuberculosis Programmes on the Management of Tuberculosis in Children<ref name="WHO TB Children"> {{cite web |url=http://apps.who.int/iris/bitstream/10665/112360/1/9789241548748_eng.pdf| title=WHO Guidance for national tuberculosis programmes on the management of tuberculosis in children, 2014}}</ref> and WHO Childhood TB: Training Toolkit <ref name="Toolkit"> {{cite web| url=http://www.who.int/tb/challenges/childtbtraining_manual/en/| title=WHO Childhood TB: Training Toolkit}}</ref></small></small></small>== | ||
*Empirical treatment should be started and the regimen should be modified according to the [[DST]] ([[Drug susceptibility testing]]) results. | |||
*Drug dosing should be calculated according the child's weight, regardless the age. | *[[Empirical|Empirica]]<nowiki/>l treatment should be started and the regimen should be modified according to the [[DST]] ([[Drug susceptibility testing]]) results. | ||
*Drug dosing should be calculated according to the child's weight, regardless the age. | |||
*Pediatricians should closely monitor adverse drug reactions and manage them appropriately. | *Pediatricians should closely monitor adverse drug reactions and manage them appropriately. | ||
*For drug resistant tuberculosis, hospitalization is often required for the administration of IV medications. | *For [[drug-resistant tuberculosis]], hospitalization is often required for the administration of IV medications. | ||
*The treatment duration for drug susceptible TB is 6 months. | *The treatment duration for drug-susceptible TB is 6 months. | ||
*The treatment duration for drug resistant tuberculosis will depend on the culture results. The duration of therapy should be at least 18 months after the culture is negative. | *The treatment duration for drug-resistant tuberculosis will depend on the culture results. The duration of therapy should be at least 18 months after the culture is negative. | ||
* | *Weight gain and resolution of symptoms are good markers for a good response to treatment. | ||
<br> | <br> | ||
<SMALL><font color="#FF4C4C">'''▸ Click on the following categories to expand treatment regimens.'''</font></SMALL> | <SMALL><font color="#FF4C4C">'''▸ Click on the following categories to expand treatment regimens.'''</font></SMALL> | ||
{| | {| | ||
| valign=top | | | valign="top" | | ||
<div style="border-radius: 5px 5px 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #A1BCDD; text-align: center;"> | <div style="border-radius: 5px 5px 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #A1BCDD; text-align: center;"> | ||
Line 229: | Line 232: | ||
</div> | </div> | ||
| valign=top | | | valign="top" | | ||
{| class="mw-collapsible mw-collapsed | {| class="mw-collapsible mw-collapsed" style="background: #FFFFFF;" | ||
| valign=top | | | valign="top" | | ||
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;" | {| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;" | ||
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Drug Susceptible TB Regimen}} | ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align="center" |{{fontcolor|#FFF|Drug Susceptible TB Regimen}} | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Initial phase <br> (Administer each drug daily for 8 weeks)''''' | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align="center" |'''''Initial phase <br> (Administer each drug daily for 8 weeks)''''' | ||
|- | |- | ||
|style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Isoniazid]] 10 mg/kg PO (Max: 300 mg/day)'''''<br> PLUS <br> ▸ '''''[[Rifampicin]] 15 mg/kg PO (Max: 600 mg/day)'''''<br> PLUS<br> ▸ '''''[[Pyrazinamide]] 35 mg/kg PO (Max: 2 g/day)'''''<br> PLUS <br> ▸ '''''[[Ethambutol]] 20 mg/kg PO (Max: 1.6 g/day)''''' | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align="left" |▸ '''''[[Isoniazid]] 10 mg/kg PO (Max: 300 mg/day)'''''<br> PLUS <br> ▸ '''''[[Rifampicin]] 15 mg/kg PO (Max: 600 mg/day)'''''<br> PLUS<br> ▸ '''''[[Pyrazinamide]] 35 mg/kg PO (Max: 2 g/day)'''''<br> PLUS <br> ▸ '''''[[Ethambutol]] 20 mg/kg PO (Max: 1.6 g/day)''''' | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Continuation phase <br> (Administer each drug daily for 18 weeks)''''' | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align="center" |'''''Continuation phase <br> (Administer each drug daily for 18 weeks)''''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left |▸ '''''[[Isoniazid]] 10 mg/kg PO (Max: 300 mg/day) '''''<br> PLUS<br> ▸ ''''' [[Rifampicin]] 15 mg/kg PO (Max: 600 mg/day )''''' | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align="left" |▸ '''''[[Isoniazid]] 10 mg/kg PO (Max: 300 mg/day) '''''<br> PLUS<br> ▸ ''''' [[Rifampicin]] 15 mg/kg PO (Max: 600 mg/day )''''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #F5F5F5;" align=left |<small>Table adapted from WHO 2013 Treatment of Tuberculosis: Guidelines – 4th ed.<ref name="WHO 2013"> {{cite web| url=http://www.who.int/tb/publications/tb_treatmentguidelines/en/| title=2013 WHO Treatment of Tuberculosis: Guidelines for National Programmes (4th Edition) }}</ref></small> | | style="font-size: 90%; padding: 0 5px; background: #F5F5F5;" align="left" |<small>Table adapted from WHO 2013 Treatment of Tuberculosis: Guidelines – 4th ed.<ref name="WHO 2013"> {{cite web| url=http://www.who.int/tb/publications/tb_treatmentguidelines/en/| title=2013 WHO Treatment of Tuberculosis: Guidelines for National Programmes (4th Edition) }}</ref></small> | ||
|} | |} | ||
|} | |} | ||
{| class="mw-collapsible mw-collapsed | {| class="mw-collapsible mw-collapsed" style="background: #FFFFFF;" | ||
| valign=top | | | valign="top" | | ||
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;" | {| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;" | ||
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|MDR-TB Regimen}} | ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align="center" |{{fontcolor|#FFF|MDR-TB Regimen}} | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Standard Regimen''''' | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align="center" |'''''Standard Regimen''''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | '''<u>Group 1: First-line oral drugs</u>''' <br> | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align="left" |'''<u>Group 1: First-line oral drugs</u>''' <br> | ||
▸ ''' [[Pyrazinamide]] 20-30 mg/kg (Max: 600 mg)''' <br> OR <br> ▸ '''[[Ethambutol]] 15-20 mg/kg''' <br> OR <br> ▸ '''[[Rifabutin]] 5 mg/kg''' | ▸ ''' [[Pyrazinamide]] 20-30 mg/kg (Max: 600 mg)''' <br> OR <br> ▸ '''[[Ethambutol]] 15-20 mg/kg''' <br> OR <br> ▸ '''[[Rifabutin]] 5 mg/kg''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align="left" |PLUS | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | '''<u>Group 2: Injectable drugs</u>''' <br> | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align="left" |'''<u>Group 2: Injectable drugs</u>''' <br> | ||
▸ '''[[Capreomycin]] 15-30 mg/kg (Max: 1000 mg)'''<br> OR <br> ▸ '''[[Kanamycin]] 15-30 mg/kg (Max: 1000 mg)'''<br> OR <br> ▸ '''[[Amikacin]] 15-22.5 mg/kg (Max: 1000 mg)'''<br> OR <br> ▸ '''[[Streptomycin]] 12-18 mg/kg''' | ▸ '''[[Capreomycin]] 15-30 mg/kg (Max: 1000 mg)'''<br> OR <br> ▸ '''[[Kanamycin]] 15-30 mg/kg (Max: 1000 mg)'''<br> OR <br> ▸ '''[[Amikacin]] 15-22.5 mg/kg (Max: 1000 mg)'''<br> OR <br> ▸ '''[[Streptomycin]] 12-18 mg/kg''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align="left" |PLUS | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | '''<u>Group 3: Fluoroquinolones</u>''' <br> | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align="left" |'''<u>Group 3: Fluoroquinolones</u>''' <br> | ||
▸ '''[[Levofloxacin]] 7.5-10 mg/kg'''<br> OR <br> ▸ '''[[Moxifloxacin]] 7.5-10 mg/kg'''<br> OR <br> ▸ '''[[Ofloxacin]] 15-20 mg/kg divided q12h (Max:800 mg)''' | ▸ '''[[Levofloxacin]] 7.5-10 mg/kg'''<br> OR <br> ▸ '''[[Moxifloxacin]] 7.5-10 mg/kg'''<br> OR <br> ▸ '''[[Ofloxacin]] 15-20 mg/kg divided q12h (Max:800 mg)''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align="left" |PLUS | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | '''<u>Group 4:Oral bacteriostatic second-line drugs</u>''' <br> | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align="left" |'''<u>Group 4:Oral bacteriostatic second-line drugs</u>''' <br> | ||
▸ '''[[Ethionamide]] 15-20 mg/kg divided q12h (Max: 1000 mg)'''<br> OR <br> ▸ '''[[Protionamide]] 15-20 mg/kg divided q12h (Max: 1000 mg)''' <br> OR <br> ▸ '''[[Cycloserine]] 10-20 mg/kg (Max: 1000 mg)'''<br> OR <br> ▸ '''[[Terizidone]] 10-20 mg/kg (Max: 1000 mg)'''<br> OR <br> ▸ '''[[Aminosalicylic acid|Para-aminosalicylic acid]] 150 mg/kg divided q8-12h(Max: 12 000 mg)''' | ▸ '''[[Ethionamide]] 15-20 mg/kg divided q12h (Max: 1000 mg)'''<br> OR <br> ▸ '''[[Protionamide]] 15-20 mg/kg divided q12h (Max: 1000 mg)''' <br> OR <br> ▸ '''[[Cycloserine]] 10-20 mg/kg (Max: 1000 mg)'''<br> OR <br> ▸ '''[[Terizidone]] 10-20 mg/kg (Max: 1000 mg)'''<br> OR <br> ▸ '''[[Aminosalicylic acid|Para-aminosalicylic acid]] 150 mg/kg divided q8-12h(Max: 12 000 mg)''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #F5F5F5;" align=left |<small>Table adapted from WHO 2013 Treatment of tuberculosis: guidelines – 4th ed.<ref name="WHO 2013"> {{cite web| url=http://www.who.int/tb/publications/tb_treatmentguidelines/en/| title=2013 WHO Treatment of Tuberculosis: Guidelines for National Programmes (4th Edition) }}</ref> and Guidance for national tuberculosis programmes on the management of tuberculosis in children <ref name="WHO TB Children"> {{cite web |url=http://apps.who.int/iris/bitstream/10665/112360/1/9789241548748_eng.pdf| title=WHO Guidance for national tuberculosis programmes on the management of tuberculosis in children, 2014}} </ref></small> | | style="font-size: 90%; padding: 0 5px; background: #F5F5F5;" align="left" |<small>Table adapted from WHO 2013 Treatment of tuberculosis: guidelines – 4th ed.<ref name="WHO 2013"> {{cite web| url=http://www.who.int/tb/publications/tb_treatmentguidelines/en/| title=2013 WHO Treatment of Tuberculosis: Guidelines for National Programmes (4th Edition) }}</ref> and Guidance for national tuberculosis programmes on the management of tuberculosis in children <ref name="WHO TB Children"> {{cite web |url=http://apps.who.int/iris/bitstream/10665/112360/1/9789241548748_eng.pdf| title=WHO Guidance for national tuberculosis programmes on the management of tuberculosis in children, 2014}} </ref></small> | ||
|} | |} | ||
|} | |} | ||
{| class="mw-collapsible mw-collapsed | {| class="mw-collapsible mw-collapsed" style="background: #FFFFFF;" | ||
| valign=top | | | valign="top" | | ||
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;" | {| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;" | ||
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|XDR-TB Regimen}} | ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align="center" |{{fontcolor|#FFF|XDR-TB Regimen}} | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Standard Regimen''''' | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align="center" |'''''Standard Regimen''''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | '''<u>Group 1: First-line oral drugs</u>''' <br> | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align="left" |'''<u>Group 1: First-line oral drugs</u>''' <br> | ||
▸ ''' [[Pyrazinamide]] 20-30 mg/kg (Max: 600 mg)''' <br> OR <br> ▸ '''[[Ethambutol]] 15 mg/kg ''' <br> OR <br> ▸ '''[[Rifabutin]] 5 mg/kg''' | ▸ ''' [[Pyrazinamide]] 20-30 mg/kg (Max: 600 mg)''' <br> OR <br> ▸ '''[[Ethambutol]] 15 mg/kg ''' <br> OR <br> ▸ '''[[Rifabutin]] 5 mg/kg''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align="left" |PLUS | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | '''<u>Group 4:Oral bacteriostatic second-line drugs</u>''' <br> | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align="left" |'''<u>Group 4:Oral bacteriostatic second-line drugs</u>''' <br> | ||
▸ '''[[Ethionamide]] 15-20 mg/kg (Max: 1000 mg)'''<br> OR <br> ▸ '''[[Protionamide]] 15-20 mg/kg (Max: 1000 mg)''' <br> OR <br> ▸ '''[[Cycloserine]] 10-20 mg/kg (Max: 1000 mg)'''<br> OR <br> ▸ '''[[Terizidone]] 10-20 mg/kg (Max: 1000 mg)'''<br> OR <br>▸ '''[[Aminosalicylic acid|Para-aminosalicylic acid]] 150 mg/kg/d divided q8-12h''' | ▸ '''[[Ethionamide]] 15-20 mg/kg (Max: 1000 mg)'''<br> OR <br> ▸ '''[[Protionamide]] 15-20 mg/kg (Max: 1000 mg)''' <br> OR <br> ▸ '''[[Cycloserine]] 10-20 mg/kg (Max: 1000 mg)'''<br> OR <br> ▸ '''[[Terizidone]] 10-20 mg/kg (Max: 1000 mg)'''<br> OR <br>▸ '''[[Aminosalicylic acid|Para-aminosalicylic acid]] 150 mg/kg/d divided q8-12h''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align="left" |PLUS | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | '''<u>Group 5</u>''' <br>'''''Use at least 2 of the following:''''' | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align="left" |'''<u>Group 5</u>''' <br>'''''Use at least 2 of the following:''''' | ||
▸ '''[[Clofazimine]] 50 mg/d AND 300 mg once a month'''<br> OR <br> ▸ '''[[Amoxicillin]]/[[clavulanate]]''' <br> OR <br> ▸ '''[[Linezolid]] 300-600 mg'''<br> OR <br> ▸ '''[[Imipenem]] 500mg q6h'''<br> OR <br>▸ '''[[Clarithromycin]] 500-1000 mg q12h '''<br> OR <br>▸ '''[[Thioacetazone]] 2.5 mg/kg'''<br> OR <br>▸ '''[[Isoniazid]] (high-dose) 16–20 mg/kg''' | ▸ '''[[Clofazimine]] 50 mg/d AND 300 mg once a month'''<br> OR <br> ▸ '''[[Amoxicillin]]/[[clavulanate]]''' <br> OR <br> ▸ '''[[Linezolid]] 300-600 mg'''<br> OR <br> ▸ '''[[Imipenem]] 500mg q6h'''<br> OR <br>▸ '''[[Clarithromycin]] 500-1000 mg q12h '''<br> OR <br>▸ '''[[Thioacetazone]] 2.5 mg/kg'''<br> OR <br>▸ '''[[Isoniazid]] (high-dose) 16–20 mg/kg''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #F5F5F5;" align=left |<small>Table adapted from WHO 2013 Treatment of tuberculosis: guidelines – 4th ed.<ref name="WHO 2013"> {{cite web| url=http://www.who.int/tb/publications/tb_treatmentguidelines/en/| title=2013 WHO Treatment of Tuberculosis: Guidelines for National Programmes (4th Edition) }}</ref> and WHO Guidance for national tuberculosis programmes on the management of tuberculosis in children <ref name="WHO TB Children"> {{cite web |url=http://apps.who.int/iris/bitstream/10665/112360/1/9789241548748_eng.pdf| title=WHO Guidance for national tuberculosis programmes on the management of tuberculosis in children, 2014}} </ref></small> | | style="font-size: 90%; padding: 0 5px; background: #F5F5F5;" align="left" |<small>Table adapted from WHO 2013 Treatment of tuberculosis: guidelines – 4th ed.<ref name="WHO 2013"> {{cite web| url=http://www.who.int/tb/publications/tb_treatmentguidelines/en/| title=2013 WHO Treatment of Tuberculosis: Guidelines for National Programmes (4th Edition) }}</ref> and WHO Guidance for national tuberculosis programmes on the management of tuberculosis in children <ref name="WHO TB Children"> {{cite web |url=http://apps.who.int/iris/bitstream/10665/112360/1/9789241548748_eng.pdf| title=WHO Guidance for national tuberculosis programmes on the management of tuberculosis in children, 2014}} </ref></small> | ||
|} | |} | ||
|} | |} | ||
|} | |} | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
{{WH}} | |||
{{WS}} | |||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category: Pulmonology]] | |||
[[Category:Pulmonology | |||
[[Category:Bacterial diseases]] | [[Category:Bacterial diseases]] | ||
Latest revision as of 03:25, 29 March 2021
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mashal Awais, M.D.[2]; Alejandro Lemor, M.D. [3]
Tuberculosis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Tuberculosis in children On the Web |
American Roentgen Ray Society Images of Tuberculosis in children |
Risk calculators and risk factors for Tuberculosis in children |
Overview
Tuberculosis in children aged 15 years or younger is considered a public health issue of special significance because it is a marker for recent transmission of TB. The likelihood of developing life-threatening forms of tuberculosis, such as miliary TB or TB meningitis is more in infants and young children. Screening in children is essential, because the signs and symptoms are usually vague or non-specific. History of close contact with tuberculosis patients plays an major role in the diagnosis of TB in children. The treatment is similar to adults, with adjustment of the doses according to the child's weight.
Screening for Tuberculosis
Symptom-based Screening Approach
Algorithm adapted from Guidance for National Tuberculosis Programmes on the Management of Tuberculosis in Children[1]
Child in close contact with a confirmed TB case | |||||||||||||||||||||||||||||||||||||||||||||||||
< 5 yrs old | > 5 yrs old | ||||||||||||||||||||||||||||||||||||||||||||||||
Asymptomatic | Symptomatic | Symptomatic | Asymptomatic | ||||||||||||||||||||||||||||||||||||||||||||||
Administer INH 10 mg/kg/d x 6 months | No preventive treatment is recommended. | ||||||||||||||||||||||||||||||||||||||||||||||||
If the child develops symptoms | If the child develops symptoms | ||||||||||||||||||||||||||||||||||||||||||||||||
Confirm the diagnosis of TB with:
| |||||||||||||||||||||||||||||||||||||||||||||||||
Screening Children with HIV
Algorithm adapted from Guidance for National Tuberculosis Programmes on the Management of Tuberculosis in Children[1]
IPT: Isoniazid preventive therapy (INH 10 mg/kg/d x 6 months)
Child with HIV and older than 1 year | |||||||||||||||||||||||||||||||||||||||||||||||||||
Does the patient has any of the following symptoms?
| |||||||||||||||||||||||||||||||||||||||||||||||||||
Yes | No | ||||||||||||||||||||||||||||||||||||||||||||||||||
Does the patient has any of the following contraindications for IPT?
| |||||||||||||||||||||||||||||||||||||||||||||||||||
TB confirmed | TB ruled out, other diagnosis confirmed | Yes | No | ||||||||||||||||||||||||||||||||||||||||||||||||
Administer 2HRZE/4HR regimen | Give appropriate treatment for the disease and consider IPT | Do not administer IPT | Administer IPT | ||||||||||||||||||||||||||||||||||||||||||||||||
Diagnosis
- Children must have a complete evaluation for tuberculosis, which includes a meticulous medical history, a complete physical examination, tuberculin skin test (TST), chest X-ray, sputum or gastric aspirate studies (microscopy and culture), and HIV testing.
- Bacteriological testing might be difficult among children, but it should be performed whenever possible.
- Adolescents usually have the adult clinical presentation, but may also present with symptoms and findings seen in smaller children.
- Even though a scoring system has been developed in some countries[2][3][4][5][6], the WHO does not recommend this system for the evaluation of children with suspected TB.[1]
Diagnostic Approach in Children with Suspected Tuberculosis | |
---|---|
History and Symptoms |
|
Physical Examination |
|
Tuberculin Skin Test |
|
Chest X-ray |
|
Bacteriological Tests |
|
HIV Test |
|
Adapted from Guidance for National Tuberculosis Programmes on the Management of Tuberculosis in Children[1] |
Diagnostic Approach for Extrapulmonary Tuberculosis
Location | Common Clinical Presentation | Diagnostic Workup |
---|---|---|
Peripheral Adenopathy | Painless lymph node enlargement, commonly in one side of the neck. | Fine needle aspiration or biopsy of the lymph node, culture of aspirate. |
Miliary Tuberculosis | Lethargy, fever, non-specific symptoms. | Order a chest X-ray and a lumbar puncture in suspicion of meningeal involvement. |
Tuberculous Meningitis | Lethargy, neck stiffness, headache, irritability, bulging fontanelle. | Lumbar puncture, head CT. |
Pleural Effusion | Decreased breath sounds, dullness to percussion, chest pain. | Order a chest X-ray, perform an analysis of the pleural fluid. |
Tuberculous Peritonitis | Order an abdominal ultrasound, consider abdominal fluid aspiration for analysis. | Abdominal tenderness, ascites. |
Bone or Joint Infection | Altered ROM, joint swelling, monoarticular pain. | X-ray of the affected limb, joint fluid aspiration and analysis. |
Tuberculous Pericarditis | Distant heart sounds, tachycardia, signs of heart failure (edema, dyspnea). | Echocardiography, consider pericardiocentesis for fluid analysis. |
Adapted from Guidance for National Tuberculosis Programmes on the Management of Tuberculosis in Children[1] and WHO Childhood TB: Training Toolkit [7]
|
Treatment Adapted from Guidance for National Tuberculosis Programmes on the Management of Tuberculosis in Children[1] and WHO Childhood TB: Training Toolkit [7]
- Empirical treatment should be started and the regimen should be modified according to the DST (Drug susceptibility testing) results.
- Drug dosing should be calculated according to the child's weight, regardless the age.
- Pediatricians should closely monitor adverse drug reactions and manage them appropriately.
- For drug-resistant tuberculosis, hospitalization is often required for the administration of IV medications.
- The treatment duration for drug-susceptible TB is 6 months.
- The treatment duration for drug-resistant tuberculosis will depend on the culture results. The duration of therapy should be at least 18 months after the culture is negative.
- Weight gain and resolution of symptoms are good markers for a good response to treatment.
▸ Click on the following categories to expand treatment regimens.
Tuberculosis in Children ▸ Drug Susceptible TB ▸ MDR-TB ▸ XDR-TB |
|
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 "WHO Guidance for national tuberculosis programmes on the management of tuberculosis in children, 2014" (PDF).
- ↑ Isabella Coimbra, Magda Maruza, Maria de Fatima Pessoa Militao Albuquerque, Joanna D.'Arc Lyra Batista, Maria Cynthia Braga, Libia Vilela Moura, Democrito Barros Miranda-Filho, Ulisses Ramos Montarroyos, Heloisa Ramos Lacerda, Laura Cunha Rodrigues & Ricardo Arraes de Alencar Ximenes (2014). "Validating a scoring system for the diagnosis of smear-negative pulmonary tuberculosis in HIV-infected adults". PloS one. 9 (4): e95828. doi:10.1371/journal.pone.0095828. PMID 24755628.
- ↑ Constantino Giovani Braga Cartaxo, Laura C. Rodrigues, Carolina Pinheiro Braga & Ricardo Arraes de Alencar Ximenes (2014). "Measuring the accuracy of a point system to diagnose tuberculosis in children with a negative smear or with no smear or culture". Journal of epidemiology and global health. 4 (1): 29–34. doi:10.1016/j.jegh.2013.10.002. PMID 24534333. Unknown parameter
|month=
ignored (help) - ↑ Sandra Christo dos Santos, Ana Maria Campos Marques, Roselene Lopes de Oliveira & Rivaldo Venancio da Cunha (2013). "Scoring system for the diagnosis of tuberculosis in indigenous children and adolescents under 15 years of age in the state of Mato Grosso do Sul, Brazil". Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia. 39 (1): 84–91. PMID 23503490. Unknown parameter
|month=
ignored (help) - ↑ Stephen M. Graham (2011). "The use of diagnostic systems for tuberculosis in children". Indian journal of pediatrics. 78 (3): 334–339. doi:10.1007/s12098-010-0307-7. PMID 21165720. Unknown parameter
|month=
ignored (help) - ↑ Emily C. Pearce, Jason F. Woodward, Winstone M. Nyandiko, Rachel C. Vreeman & Samuel O. Ayaya (2012). "A systematic review of clinical diagnostic systems used in the diagnosis of tuberculosis in children". AIDS research and treatment. 2012: 401896. doi:10.1155/2012/401896. PMID 22848799.
- ↑ 7.0 7.1 "WHO Childhood TB: Training Toolkit".
- ↑ 8.0 8.1 8.2 "2013 WHO Treatment of Tuberculosis: Guidelines for National Programmes (4th Edition)".